Anti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
List view / Grid view
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.